VIAP — VIA Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $13.92m
Annual income statement for VIA Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2006 December 31st | 2007 December 31st | 2008 December 31st | 2009 December 31st | 2010 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 8.22 | 22.3 | 20.5 | 13.3 | 6.02 |
| Operating Profit | -8.22 | -22.3 | -20.5 | -13.3 | -6.02 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.63 | -21.8 | -20.3 | -21 | -9.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.63 | -21.8 | -20.3 | -21 | -9.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.63 | -21.8 | -20.3 | -21 | -9.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -8.63 | -21.8 | -20.3 | -21 | -9.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -19.8 | -1.85 | -1.03 | -1.05 | -0.465 |
| Dividends per Share |